Key facts
- This page summarizes Salim Yazji's Form 4 filing for Oncternal Therapeutics, Inc..
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 05 Jan 2024, 16:00.
Salim Yazji - 03 Jan 2024 Form 4 Insider Report for Oncternal Therapeutics, Inc.
- Reporting relationship
- Chief Medical Officer
- Issuer ticker
- N/A
- Reported as of
- 03 Jan 2024
- Net transaction value
- -$9,794
- SEC form
- 4
- Accepted by SEC
- 05 Jan 2024, 16:00:25 UTC
- Prior SEC filing
- 04 Oct 2023
- Next SEC filing
- 15 Feb 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/Chase C. Leavitt, Attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Salim Yazji filed Form 4 for Oncternal Therapeutics, Inc. on 05 Jan 2024.
Change
- Previous filing in this sequence was filed on 04 Oct 2023.
- Current net transaction value: -$9,794.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ONCT
transaction
Common Stock
Tax liability
- Transaction value
- $9,794
- Shares
- -19,742
- Change %
- -13%
- Price
- $0.4961
- Shares after
- 128,635
- Date
- 03 Jan 2024
- Ownership
- Direct
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
Shares withheld by the Issuer to satisfy statutory tax withholding requirements on vesting of restricted stock units.